Alfaloun Pharma Aims for 800M Riyals in Terzibataide Sales

Avalon Pharma has confirmed that it expects to generate cumulative revenues exceeding 800 million SAR during the first five years of launching the drug "Terzipatide" in Saudi Arabia and the Middle East and North Africa markets, under an exclusive licensing agreement with an Indian company. The agreement grants the company rights to register and market the medication, which is a multi-dose pen with doses ranging from 2.5 to 15 mg, and is a generic version of Munjaro Quick Pen. The product is expected to be launched after patent expiration. The agreement lasts for 10 years with the possibility of annual renewal, and Avalon Pharma has the right to transfer manufacturing technology. This partnership enhances the company's portfolio of diabetes and metabolic disorder medications and supports its expansion in line with Vision 2030.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل